文献速递前列腺增生与排尿功能障碍

前列腺动脉栓塞术治疗良性前列腺增生男性患者:一项Cochrane系统评价

Prostatic arterial embolisation for men with benign prostatic hyperplasia: a Cochrane review.
PubMed 文献 · BJU Int · 2022-07-13

这项Cochrane系统评价比较了前列腺动脉栓塞术(PAE)与其他手术(主要为经尿道前列腺电切术TURP)治疗良性前列腺增生(BPH)所致下尿路症状的效果。短期和长期随访中,PAE与TURP在泌尿症状评分和生活质量上可能几乎无差异,但主要不良事件比较存在很大不确定性。

要点

  • 短期随访:PAE与TURP的泌尿症状评分改善可能几乎无差异(MD 1.72,95%CI -0.37至3.81;低证据质量)。
  • 长期随访:PAE与TURP的泌尿症状评分可能几乎无差异(MD 2.58,95%CI -1.54至6.71;低证据质量)。
  • 主要不良事件比较存在很大不确定性(短期RR 0.75,95%CI 0.19-2.97;长期RR 0.91,95%CI 0.20-4.05;极低证据质量)。

核心结论

  • 与TURP相比,PAE对患者感知的泌尿症状和生活质量改善的影响似乎相似。
  • 本评价显示主要不良事件的比较存在很大不确定性。

研究设计与样本

  • Cochrane系统评价,纳入随机对照试验(RCT)和非随机研究(NRS),全面检索截至2021年11月8日。
  • 纳入接受PAE或其他手术干预的BPH男性患者。
  • 由两名独立评价者筛选文献、提取数据、评估偏倚风险,采用随机效应模型进行统计分析,并对RCT和NRS的证据质量(CoE)进行评级。

主要发现

  • 共发现数据支持两项比较:PAE vs 经尿道前列腺电切术(TURP;6项RCT和2项NRS),以及PAE vs 假手术(1项RCT)。
  • 短期随访(基于RCT证据):PAE与TURP在泌尿症状评分改善上可能几乎无差异(MD 1.72,95%CI -0.37至3.81;低CoE)。
  • 短期随访(基于RCT证据):PAE与TURP在生活质量(QoL)上可能几乎无差异(MD 0.28,95%CI -0.28至0.84;低CoE),采用国际前列腺症状评分测量。
  • 短期随访:PAE对主要不良事件的影响非常不确定(RR 0.75,95%CI 0.19-2.97;极低CoE)。
  • 长期随访(基于RCT证据):PAE与TURP在泌尿症状评分上可能几乎无差异(MD 2.58,95%CI -1.54至6.71;低CoE)。

关键数值与推荐

  • 短期随访:泌尿症状评分MD 1.72(95%CI -0.37至3.81;低CoE)。
  • 短期随访:生活质量MD 0.28(95%CI -0.28至0.84;低CoE)。
  • 短期随访:主要不良事件RR 0.75(95%CI 0.19-2.97;极低CoE)。
  • 长期随访:泌尿症状评分MD 2.58(95%CI -1.54至6.71;低CoE)。
  • 长期随访:生活质量MD 0.50(95%CI -0.03至1.04;低CoE)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the effects of prostatic arterial embolisation (PAE) compared to other procedures for treatment of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH). METHODS: We included randomised controlled trials (RCTs), as well as non-randomised studies (NRSs) enrolling men with BPH undergoing PAE vs other surgical interventions via a comprehensive search up until 8 November 2021. Two independent reviewers screened the literature, extracted data, assessed risk of bias, performed statistical analyses by using a random-effects model, and rated the certainty of evidence (CoE) of RCTs and NRSs. RESULTS: We found data to inform two comparisons: PAE vs transurethral resection of prostate (TURP; six RCTs and two NRSs), and PAE vs sham (one RCT). This abstract focuses on the primary outcomes in a comparison of PAE vs TURP. Short-term follow-up: based on RCT evidence, there may be little to no difference in urological symptom score improvement (mean difference [MD] 1.72, 95% confidence interval [CI] -0.37 to 3.81; low CoE) and quality of life (QoL; MD 0.28, 95% CI -0.28 to 0.84; low CoE) measured by International Prostatic Symptom Score. We are very uncertain about the effects of PAE on major adverse events (risk ratio [RR] 0.75, 95% CI 0.19-2.97; very low CoE). Long-term follow-up: based on RCT evidence, PAE may result in little to no difference in urological symptom scores (MD 2.58, 95% CI -1.54 to 6.71; low CoE) and QoL (MD 0.50, 95% CI -0.03 to 1.04; low CoE). We are very uncertain about major adverse events (RR 0.91, 95% CI 0.20-4.05; very low CoE). CONCLUSION: Compared to TURP, the impact on urological symptoms and QoL improvement as perceived by patients appears to be similar. This review did reveal major uncertainty as to how major adverse events compare.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Jung JH, McCutcheon KA, Borofsky M, et al. Prostatic arterial embolisation for men with benign prostatic hyperplasia: a Cochrane review. BJU Int. 2022. PMID: 35696302. doi:10.1111/bju.15823

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。